Medplus Subsidiary Optival Receives Two Drug License Suspension Orders
Medplus subsidiary Optival Health Solutions received two drug license suspension orders. A Telangana store faces a 3-day suspension (potential loss ₹1.69 lacs), and a Maharashtra store faces a 7-day suspension (potential loss ₹3.85 lacs). The orders are related to alleged violations of the Drugs and Cosmetics Act.
While two stores are affected, the total potential revenue loss is relatively small (₹1.69 lacs + ₹3.85 lacs = ₹5.54 lacs) compared to the overall business of Medplus. However, it indicates regulatory compliance issues.
The company's subsidiary received suspension orders for drug licenses, which will directly impact its operations and revenue. This is a negative development.
Medplus Health Services Limited announced that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for drug licenses of its stores. The first order pertains to a store located in Jawahar Nagar, Telangana, with its drug license suspended for three days. This order was received on December 24, 2025, and is reportedly due to a violation under Rule 65 of the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945. The potential revenue loss for this suspension is estimated at approximately ₹1.69 lacs.
The second suspension order is for a store located in Radha Nagar-Kalyan, Maharashtra, where the drug license has been suspended for seven days. The authority issuing this order is the Food and Drug Administration, Mumbai, Maharashtra. The potential revenue loss associated with this suspension is estimated at approximately ₹3.85 lacs.
These details are being shared pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The information will be available on the company's website and the websites of BSE Limited and the National Stock Exchange of India Ltd.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.